Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study

AIMS: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first‐line treatment for patients with unresectable MPM. Recently, promising outcomes were observed with first‐line bevacizumab com...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Takashi, Kuribayashi, Kozo, Kondo, Masashi, Morise, Masahiro, Tada, Yuji, Hirano, Katsuya, Hayashi, Morihiko, Tanaka, Misa, Hirabayashi, Masataka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246920/
https://www.ncbi.nlm.nih.gov/pubmed/32893992
http://dx.doi.org/10.1111/ajco.13455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246920/
https://www.ncbi.nlm.nih.gov/pubmed/32893992
http://dx.doi.org/10.1111/ajco.13455

Ejemplares similares